Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharm > Hemostasis > Flashcards

Hemostasis Flashcards

1
Q

Platelets

A

150-400,000 per microliter of blood. 33% in spleen. life span 8-12 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

3 steps of primary hemostasis

A

Adhesion, Activation, Aggregation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Adhesion of Platelets

A

Factor needed: Von Willebrand’s Factor
surrounding endothelial cells synthesize and release VWF. VWF binds to the damaged endothelial wall and to GP1B receptor. GP1B receptor binds platelets.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Activation of Platelets

A

Factor needed: thrombin (factor II). Thrombin binds to activate platelets. Activation of platelets results in the production of thromboxane 2A and ADP.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Thrombin + Platelets –> Thromboxane A2 and ADP

A

thrombin + platelets = phospholipase with convert phospholipids into arachidonic acid which = prostaglandin G2. PGG2 is metabolized to PGH2 which converts to thromboxane A2 and ADP.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Aspirin effect on platelets

A

Irreversibly inhibits COX-1. for the life of the platelet 8-12 days. COX stops the conversion of arachidonic acid to PGG2 therefore inhibiting thromboxane A2 and ADP production.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

NSAID effect on platelets

A

Reversibly inhibits COX 1, stop 24-48 hrs. COX stops the conversion of arachidonic acid to PGG2 therefore inhibiting thromboxane A2 and ADP production.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Aggregation of Platelets

A

Thromboxane A2 and ADP uncover fibrinogen receptors on the platelets to bind the platelets together. clot formation begins here but is still water soluble and friable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Secondary Hemostasis Steps

A

Production of fibrin. Extrinsic or intrinsic pathway to the final common pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Production of Fibrin

A

factor needed: factor XIII. crosslinks and weaves the platelets together. XIII is activated via either Extrinsic or Intrinsic pathway ending in the final common pathway.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Intrinsic Pathway

A

XII - XI - IX - VIII. damage occurs inside blood vessel.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Extrinsic

A

III - VII. damage occurs external to blood vessel.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Final Common Pathway

A

X - V - II - I - XIII

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Coumadin

A

Acts on extrinsic and final common pathway. Prothrombin and INR.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Heparin

A

Forms complex with antithrombin III = 1000 fold increase
Acts on intrinsic and final common pathway
Inhibits IIa & Xa, depresses IX, XI, XII
rapid onset, 6 hr duration
Dose 5000 units for DVT
met: liver, elimination: reticuloendothelial system
Monitor PTT and ACT. Half life is 1.5hrs. Stop 6 hours prior to surgery.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Hemophilia A

A

Disorder of fibrin - factor VIII (intrinsic). sex linked genetic disorder. primarily affects males but carried by female.

TX: FFP or cryo – contains factor VIII
Preferred replacement is a factor VIII pooled plasma product

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Hemophilia B

A

factor IX deficiency. Tx concentrated preparations of factor IX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Von Willebrands Disease

A

increased bleeding time with normal platelet count and clot retraction. insufficient synthesis of VWF. Treat with DDVAP which releases and stores endogenous VWF. second line is cryo or factor VIII concentrate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Fibrinolysis

A

plasmin breaks down fibrin into fibrin split products

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Plasminogen

A

Synthesized in the liver, circulates in the blood. during clot formation is incorporated into the growing thrombus. Plasminogen activates to plasmin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Plasminogen activators

A 
tpa - tissue type plasminogen activator 
- produced by endothelial cells
upa- urokinase type plasminogen activator
streptokinase
-produced by b hemolytic streptococci
22
Q

Anti-fibrinolytics

A

Aprotinin, Epsilon aminocaproic acid (Amicar, EACA) and tranexamic acid

23
Q

Aprotinin

A

inhibits plasmin = slowing of fibrin breakdown. Used during cardiac surgery to decrease intraop blood loss.

24
Q

Epsilon aminocaproic acid (Amicar, EACA) & tranexamic acid

A

prevent the breakdown of fibrin by preventing displacement of the plasmin from the fibrin
May be beneficial in hemorrhage control.

25
Q

DIC

A

from underlying disease (sepsis, hemolysis - massive transfusion, ischemia, brain trauma, hypotension/hypoperfusion, OB emergencies).

shock, ischemia, and infection are the most common in the surgical populations

Labs reflect consumption of factors and enhanced fibrinolysis. Decreased plts, fibrinogen, prothrombin, factors V, VIII, XIII. Increased fibrin degradation split products.

26
Q

Liver Disease

A

most common cause of an isolated high PT.
Defects in coagulation.
1. formation of platelet plug - thrombocytopenia from hypersplenism and platelet dysfunction from increased fibrin degradation products.
2. formation of fibrin clot on platelet surface. synthesis of all coag factors is decreased (EXCEPT VIII). increased fibrin split products interfere with fibrin polymerization
3. Fibrinolysis. increased lytic activity due to poor clearance of tpa.

Tx: replace clotting factors - cryo, FFP, vitamin K

27
Q

Renal Failure

A

uremia is an anticoagulant. Platelet dysfunction -
adherence to subendothelial collagen & synthesis of thromboxane A2 is impaired.
• Lower concentration of ADP
• Platet transfusion is ineffective- transfused plts become abnormal
• Fibrinogen and other clotting factors are decreased, fibrinolytic system is impaired.
Tx: dialysis and increased hct. cryo and DDVP may help the bleeding.

28
Q

Multiple Transfusions

A

transfused blood is deficient in clotting factors V & VIII and platelets. Diffuse bleeding during transfusion is usually from thrombocytopenia
o TX: platelets, FFP, cryo
Cryo is a primary source for I, VIII, XIII

29
Q

Cryoprecipitate

A

Cryo is a primary source for I, VIII, XIII

30
Q

ASA - acetylsalicyclic acid

A

anti-platelet, irreversible COX 1 inhibitor. half life 20 min. stop 7 days prior to surgery

31
Q

Clopidogrel (Plavix)

A

ADP receptor antagonist - inhibits activation of GP2B receptors which bind platelets. Stop 5-7 days prior to surgery.

32
Q

LMWH

A 
anti-coagulant. antagonizes factor IIa & Xa (indirect). 
4.5 hr half life.
Monitor anti-factor Xa. 
Stop 12-24 hrs prior. 
Protamine is the reversal.
33
Q

Warfarin

A

anti-coagulant.
Vitamin K epoxide reductase antagonist.
Half life 2-4 days.
stop 5 days before surgery
Monitor: PT
Reversal: Vit K, FFP, recombinant factor VII

34
Q

Bleeding Time

A

3-7 min. Measures platelet function- adhesion & aggregation. Modest prolongations do not predict surgical bleeding. Altered by NSAIDs & Aspirin.

35
Q

Platelet Count

A

150-400,000

36
Q

Thrombocytopenia

A

Platelets < 100,000

37
Q

Surgical Risk

A

platelets < 50,000

38
Q

Spontaneous Bleeding

A

Platelets < 20,000

39
Q

Prothrombin Time

A

PT 12-14s. Prolonged with extrinsic & common pathway disorders, altered by Coumadin derivatives

40
Q

Activated partial thromboplastin time

A

aPTT 25-32s. Prolonged w intrinsic & common pathway disorders. altered by heparin & lovenox.

41
Q

Thrombin Time

A

8-12s. common pathway. measures fibrinogen to fibrin action.

42
Q

ACT

A

activated clotting time - 80-150s. guides anticoagulant dosing.

43
Q

Fibrinogen

A

> 150mg/dL

44
Q

Fibrinogen degredation products

A

<10mcg/ml. measures byproducts from clot dissolution

45
Q

D-dimer

A

<500mg/ml - measures degradation products secondary to fibrinolysis

46
Q

Antithrombin III

A

80-120%. decreased level may explain sub therapeutic heparin. is severely decreased in DIC.

Antithrombin neutralizes intrinsic & final common factors. inhibits II & X, depresses IX, XI, XII

Antithrombin deficiency: liver cirrhosis, nephrotic syndrome

47
Q

tPA

A

fibrinolytic - plasminogen activator. half life is 23 minutes.
stop 3 hours prior to surgery.
monitor PT/PTT.
produced by endothelial cells

48
Q

Tranexamic Acid - TXA

A

antifibrinolytic - synthetic reversible competitive inhibitor of the lysine receptor on plasminogen. binding to the receptor prevents plasmin from binding = stabilization of fibrin clot.
use: prevent bleeding/transfusion need
IV or PO
1g over 10 min, can do another within 8 hrs, MAX 2g
elimination: really unchanged
XXX in intracranial bleeding & thromboembolic
rapid infusion can cause hypotension

49
Q

protamine

A 
heparin reversal. 
forms inactive compound with heparin 
dose dep on heparin 1mg/100 units of heparin 
admin < 5mg/min
5 min onset 
2 hr DOA = rebound bleeding
M & E: reticuloendothelial system

Consideration: histamine release = hypotension, pulm HTN, circulatory collapse, facial flushing, bronchoconstriction

50
Q

TEG

A 
measures clot formation over time
1 - platelet reactions
2- coagulation 
3 - fibrinolysis
provide information of clot strength, platelet number & function, intrinsic defects, thrombin action, rate of fibrinolysis
51
Q

Upa

A

Urokinase is the most widely used thrombolytic agent for intra-arterial infusion into the peripheral arterial system and grafts.

Pharm (11 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions